Sacituzumab govitecan (4) – Trodelvy®
Triple-negative breast cancer, first-line treatment, PD-L1 expression ≥ 10 (CPS), in combination with pembrolizumab
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Sacituzumab govitecan |
| Brand name | Trodelvy® |
| Pharm. company | Gilead Sciences GmbH |
| G-BA Procedure ID | D-1379 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Sacituzumab govitecan (4) | Trodelvy® | Gilead Sciences GmbH | Triple-negative breast cancer, first-line treatment, PD-L1 expression ≥ 10 (CPS), in combination with pembrolizumab | n.d. | active procedure | |
| Sacituzumab govitecan (3) | Trodelvy® | Gilead Sciences GmbH | Triple-negative breast cancer, first-line treatment | n.d. | active procedure | |
| Sacituzumab govitecan (2) | Trodelvy® | Gilead Sciences GmbH | Breast carcinoma, HR+, HER2-, at least 3 prior therapies | 2,480–8,240 | 100% Indication of considerable additional benefit | |
| Sacituzumab govitecan (1) | Trodelvy® | Gilead Sciences GmbH | Breast cancer (BC) triple-negative, after 2 previous therapies | 1,150–2,370 | 100% Indication of major additional benefit |
<< List of all resolutions